Letter from the CEO
As the end of 2022 approaches, I’d like to take the opportunity to thank you all for your support for SciBase and review some of the highlights of an extremely eventful year.2022 has been a breakthrough year for SciBase. We have seen impressive sales growth in key markets, important progress in the US and the establishment of our third application segment skin barrier in a year capped off by the signing of our agreement with J&J Consumer. Probably the most pleasing single aspect of 2022 has been the considerable increase in the usage of our test by clinicians. We are averaging around 10,